Lupin launches oral PDE-5 inhibitor ‘Cialis’ in India

16 May 2017 Evaluate

Lupin has launched Cialis (tadalafil), an oral PDE-5 inhibitor, for the treatment of erectile dysfunction (ED) in adult males. Cialis was shown to improve erectile function compared to placebo up to 36 hours following dosing. Cialis tablet is available in 10 mg and 20 mg strengths. The product is currently marketed in over 100 countries.

Lupin has acquired the rights to market, promote and distribute Lilly’s Erectile Dysfunction (ED) product, Cialis through its specialty field force while Lilly will be responsible for manufacturing and importing the product. Lupin is already promoting and distributing Lilly’s Huminsulin range of products and rapid acting insulin analog under the brand names Lispro and Eglucent.

The PDE-5 market in India is valued at around Rs 390 crore, out of which Tadalafil contributes around 23%. The market size has doubled since 2012 and is growing annually at 15%.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.


Lupin Share Price

2128.50 -22.55 (-1.05%)
01-Feb-2026 11:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.00
Dr. Reddys Lab 1223.00
Cipla 1328.00
Zydus Lifesciences 886.85
Lupin 2128.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×